Medicine and Dentistry
Pulmonary Hypertension
96%
Heart Right Ventricle Function
56%
Prostacyclin
48%
Acute Respiratory Distress Syndrome
40%
Transthoracic Echocardiography
30%
Brain Natriuretic Peptide
25%
Pericardial Fluid
23%
Right Ventricular Function
23%
Observational Study
21%
Meta-Analysis
20%
Systematic Review
20%
Apoplexy
20%
Chronic Obstructive Pulmonary Disease
20%
Riociguat
20%
Prostanoid
19%
Amino Terminal Sequence
17%
Treprostinil
15%
Oxygen Saturation
12%
Hemodynamic
12%
Echocardiography
11%
Exercise
11%
Retrospective Cohort Study
10%
Tricuspid Insufficiency
10%
Systolic Blood Pressure
9%
Oxygen Consumption
8%
Lung Artery Pressure
8%
Transplantation
7%
SOFA Score
6%
APACHE II
6%
SAPS II
6%
Hormone Precursor
5%
Prevalence
5%
Keyphrases
Pulmonary Arterial Hypertension
40%
Prostanoids
26%
Massive Hemoptysis
20%
Group 3 Pulmonary Hypertension
20%
Inhalable Dry Powder
20%
Tyvaso
20%
Hypertension Patients
20%
Pericardial Effusion
20%
Loeys-Dietz Syndrome
20%
Prostacyclin Therapy
20%
Low Risk
12%
IV Therapy
12%
Treprostinil
12%
High Risk
12%
Brain Natriuretic Peptide
8%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
8%
Functional Class
8%
Epoprostenol
8%
6-minute Walk Distance (6MWD)
8%
Large Pericardial Effusion
6%
Hypertension Management
6%
Echocardiogram
6%
Transforming Growth factor-β2 (TGF-β2)
5%
Simplified Acute Physiology Score II
5%
Group 1 Pulmonary Hypertension
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
100%
Treprostinil
32%
Brain Natriuretic Peptide
22%
Clinical Study
20%
Tolerability
20%
Randomized Controlled Trial
20%
Phosphodiesterase V Inhibitor
20%
Riociguat
20%
Prostanoid
14%
Prostacyclin
8%
Cohort Study
6%
Hormone Precursor
6%
Prevalence
5%
Adverse Event
5%
